MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2020002074

Медицинская библиотека · Blood advances · 2020

Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation.

Kalin Burak, van Norden Yvette, van Gelder Michel, Breems Dimitri, Maertens Johan, Jongen-Lavrencic Mojca, Broers Annoek E C, Braakman Eric, Grob Tim, Zeijlemaker Wendelien, Ossenkoppele Gert J, Meijer Ellen, Cornelissen Jan J

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of epigenetic therapy with panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess blasts with International Prognostic Scoring System score ≥1.5. A total of 140 poor-risk patients with AML aged 18 to 70 years were registered, and 110 proceeded to allo-HSCT. Three dose levels were evaluated for dose-limiting toxicities, including panobinostat monotherapy 20 mg at days 1, 4, 8, and 11 of a 4-week cycle (PNB mono group) and panobinostat combined with either decitabine 20 mg/m2 (PNB/DAC20 group) or decitabine 10 mg/m2 (PNB/DAC10 group) at days 1 to 3 of every 4-week cycle. After phase 1, the study continued as phase 2, focusing on completion of protocol treatment and treatment outcome. PNB mono and PNB/DAC10 were feasible, whereas PNB/DAC20 was not related to prolonged cytopenia. Sixty of 110 patients who underwent transplantation were eligible to receive their first DLI within 115 days after allo-HSCT. Grade 3 and 4 adverse events related to panobinostat and decitabine were observed in 23 (26%) of the 87 patients, and they received epigenetic therapy. Cumulative incidence of relapse was 35% (standard error [SE] 5), and overall survival and progression-free survival at 24 months were 50% (SE 5) and 49% (SE 5). Post-allo-HSCT epigenetic therapy with panobinostat alone or in combination with low-dose decitabine is feasible and is associated with a relatively low relapse rate. The trial was registered at the European Clinical Trial Registry, https://www.clinicaltrialsregister.eu, as ECT2012-003344-74.

Для цитирования: Kalin Burak, van Norden Yvette, van Gelder Michel, Breems Dimitri, Maertens Johan, Jongen-Lavrencic Mojca, Broers Annoek E C, Braakman Eric, Grob Tim, Zeijlemaker Wendelien, Ossenkoppele Gert J, Meijer Ellen, Cornelissen Jan J. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation.. Blood advances. 2020. DOI: 10.1182/bloodadvances.2020002074.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.